Lambert-Eaton Myasthenic Syndrome with Associated Malignancy: Next-Line Treatment After Azathioprine-Based Therapy Has Not Achieved Target Lymphocyte Count

Clinical Scenario

This protocol addresses paraneoplastic Lambert-Eaton myasthenic syndrome (pLEMS) — LEMS occurring in the context of an associated malignancy. LEMS can be idiopathic or, less commonly, paraneoplastic; the paraneoplastic form is seen especially in small-cell lung cancer (SCLC), predominantly in long-time smokers.

Previous Treatment — Failure Condition

This is a next-step protocol for patients in whom the prior regimen — glucocorticosteroids combined with azathioprine — has not achieved an absolute lymphocyte count of 600–1000/μl during azathioprine therapy. Non-achievement of this lymphocyte target is the criterion for escalation to the present protocol.

Treatment Approach (Partial)

The structured protocol specifies an alternative immunosuppressive agent to replace azathioprine, used in combination with glucocorticosteroids, and identifies a particular agent that should be avoided in this paraneoplastic setting. Full agent selection, sequencing, and clinical rationale are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/17562864231213240

LEMS can be idiopathic (iLEMS; mostly women younger than 50 years) or, less commonly – especially in small-cell lung cancer (SCLC) – as a paraneoplastic disease (pLEMS; mostly in long-time smokers).

As an alternative to AZA, treatment with MMF, CSA, tacrolimus, or RTX should be considered if appropriate.

MTX should be avoided, especially in the case of pLEMS in BC and radiation of the lung.

View source ↗